JP2010501576A - ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法 - Google Patents

ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法 Download PDF

Info

Publication number
JP2010501576A
JP2010501576A JP2009525648A JP2009525648A JP2010501576A JP 2010501576 A JP2010501576 A JP 2010501576A JP 2009525648 A JP2009525648 A JP 2009525648A JP 2009525648 A JP2009525648 A JP 2009525648A JP 2010501576 A JP2010501576 A JP 2010501576A
Authority
JP
Japan
Prior art keywords
day
effective amount
therapeutically effective
vitamin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501576A5 (enExample
Inventor
エイチ．アウエルバクフ アラン
エス．ベルルデグルン アリエ
Original Assignee
クオウガル バイオテクノロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クオウガル バイオテクノロジー，インコーポレイテッド filed Critical クオウガル バイオテクノロジー，インコーポレイテッド
Publication of JP2010501576A publication Critical patent/JP2010501576A/ja
Publication of JP2010501576A5 publication Critical patent/JP2010501576A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009525648A 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法 Pending JP2010501576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Publications (2)

Publication Number Publication Date
JP2010501576A true JP2010501576A (ja) 2010-01-21
JP2010501576A5 JP2010501576A5 (enExample) 2010-10-07

Family

ID=39107444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525648A Pending JP2010501576A (ja) 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法

Country Status (9)

Country Link
EP (2) EP2425874A3 (enExample)
JP (1) JP2010501576A (enExample)
KR (1) KR20090060306A (enExample)
CN (1) CN101528309A (enExample)
AU (1) AU2007287099A1 (enExample)
CA (2) CA2661546A1 (enExample)
IL (1) IL197212A0 (enExample)
NO (1) NO20091191L (enExample)
WO (1) WO2008024485A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015227335A (ja) * 2009-01-27 2015-12-17 バーグ バイオシステムズ，エルエルシー 化学療法に付随する副作用を軽減するためのビタミンｄ３およびその類似体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US20120135002A1 (en) * 2009-07-16 2012-05-31 Ivan Cruz Moura Compounds and Methods for the Treatment of Cancer
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
JP2016530219A (ja) 2013-06-05 2016-09-29 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｃｘｃｌ１２活性に関与する疾患を処置するためのビタミンｄ受容体アゴニスト
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
DK0633893T3 (da) * 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
JPN5009015872; Ｋｏｓｈｉｚｕｋａ　Ｋ: 'Ｃｏｍｂｉｎｅｄ　ｅｆｆｅｃｔ　ｏｆ　ｖｉｔａｍｉｎ　Ｄ３　ａｎａｌｏｇｓ　ａｎｄ　ｐａｃｌｉｔａｘｅｌ　ｏｎ　ｔｈｅ　ｇｒｏｗｔｈ　ｏｆ　ＭＣＦ-７　ｂｒｅａｓｔ　ｃａｎｃｅｒ　ｃｅｌｌｓ　ｉｎ　ｖ' Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓ　Ｔｒｅａｔ． ５３（２）, 199901, １１３-１２０ *
JPN6012057652; Ｆｌａｉｇ　ＴＷ: 'Ａ　ｐｈａｓｅ　ＩＩ　ｔｒｉａｌ　ｏｆ　ｄｅｘａｍｅｔｈａｓｏｎｅ，　ｖｉｔａｍｉｎ　Ｄ，　ａｎｄ　ｃａｒｂｏｐｌａｔｉｎ　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｈｏｒｍｏｎｅ-ｒｅｆｒａｃｔｏｒｙ　ｐｒ' Ｃａｎｃｅｒ １０７（２）, 20060715, ２６６-７４ *
JPN6012057656; Ｂｅｅｒ　ＴＭ　ｅｔ　ａｌ．: 'Ｗｅｅｋｌｙ　ｈｉｇｈ-ｄｏｓｅ　ｃａｌｃｉｔｒｉｏｌ　ａｎｄ　ｄｏｃｅｔａｘｅｌ　ｉｎ　ｍｅｔａｓｔａｔｉｃ　ａｎｄｒｏｇｅｎ-ｉｎｄｅｐｅｎｄｅｎｔ　ｐｒｏｓｔａｔｅ　ｃａｎｃｅｒ．' Ｊ　Ｃｌｉｎ　Ｏｎｃｏｌ ２１（１）, 200311, １２３-８ *
JPN6012057659; Ｔｒｕｍｐ　ＤＬ　ｅｔ　ａｌ．: 'Ｐｈａｓｅ　ＩＩ　ｔｒｉａｌ　ｏｆ　ｈｉｇｈ-ｄｏｓｅ，　ｉｎｔｅｒｍｉｔｔｅｎｔ　ｃａｌｃｉｔｒｉｏｌ　（１，２５　ｄｉｈｙｄｒｏｘｙｖｉｔａｍｉｎ　Ｄ３）　ａｎｄ　ｄｅｘａｍｅｔｈａｓｏｎｅ　ｉｎ' Ｃａｎｃｅｒ １０６（１０）, 20060515, ２１３６-４２ *
JPN6012057667; Ｖｉｎｋ-ｖａｎ　Ｗｉｊｎｇａａｒｄｅｎ　Ｔ　ｅｔ　ａｌ．: 'Ｉｎｈｉｂｉｔｉｏｎ　ｏｆ　ｂｒｅａｓｔ　ｃａｎｃｅｒ　ｃｅｌｌ　ｇｒｏｗｔｈ　ｂｙ　ｃｏｍｂｉｎｅｄ　ｔｒｅａｔｍｅｎｔ　ｗｉｔｈ　ｖｉｔａｍｉｎ　Ｄ３　ａｎａｌｏｇｕｅｓ　ａｎｄ　ｔａｍｏｘｉｆｅ' Ｃａｎｃｅｒ　Ｒｅｓ． ５４（２１）, 199411, ５７１１-７ *
JPN6012057670; Ｃｏｌｓｔｏｎ　ＫＷ　ｅｔ　ａｌ．: 'Ｍｅｃｈａｎｉｓｍｓ　ｉｍｐｌｉｃａｔｅｄ　ｉｎ　ｔｈｅ　ｇｒｏｗｔｈ　ｒｅｇｕｌａｔｏｒｙ　ｅｆｆｅｃｔｓ　ｏｆ　ｖｉｔａｍｉｎ　Ｄ　ｉｎ　ｂｒｅａｓｔ　ｃａｎｃｅｒ．' Ｅｎｄｏｃｒ　Ｒｅｌａｔ　Ｃａｎｃｅｒ ９（１）, 200203, ４５-５９ *
JPN6012057673; Ｄａｎｉｌｅｎｋｏ　Ｍ　ｅｔ　ａｌ．: 'Ｅｎｈａｎｃｅｍｅｎｔ　ｂｙ　ｏｔｈｅｒ　ｃｏｍｐｏｕｎｄｓ　ｏｆ　ｔｈｅ　ａｎｔｉ-ｃａｎｃｅｒ　ａｃｔｉｖｉｔｙ　ｏｆ　ｖｉｔａｍｉｎ　Ｄ（３）　ａｎｄ　ｉｔｓ　ａｎａｌｏｇｓ．' Ｅｘｐ　Ｃｅｌｌ　Ｒｅｓ． ２９８（２）, 20040815, ３３９-５８ *
JPN7012004504; Ｍａｓｕｄａ　Ｓ　ｅｔ　ａｌ．: 'Ｐｒｏｍｉｓｅ　ｏｆ　ｖｉｔａｍｉｎ　Ｄ　ａｎａｌｏｇｕｅｓ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｈｙｐｅｒｐｒｏｌｉｆｅｒａｔｉｖｅ　ｃｏｎｄｉｔｉｏｎｓ．' Ｍｏｌ　Ｃａｎｃｅｒ　Ｔｈｅｒ． ５（４）, 200604, ７９７-８０８ *
JPN7012004505; Ｐｅｅｈｌ　ＤＭ: 'Ｐｒｅｃｌｉｎｉｃａｌ　ａｃｔｉｖｉｔｙ　ｏｆ　ｋｅｔｏｃｏｎａｚｏｌｅ　ｉｎ　ｃｏｍｂｉｎａｔｉｏｎ　ｗｉｔｈ　ｃａｌｃｉｔｒｉｏｌ　ｏｒ　ｔｈｅ　ｖｉｔａｍｉｎ　Ｄ　ａｎａｌｏｇｕｅ　ＥＢ　１０８' Ｊ　Ｕｒｏｌ． １６８（４　Ｐｔ　１）, 200210, １５８３-８ *
JPN7012004506; Ｃｈｒｉｓｔｅｎｓｅｎ　ＧＬ　ｅｔ　ａｌ．: 'Ｓｅｑｕｅｎｔｉａｌ　ｖｅｒｓｕｓ　ｃｏｍｂｉｎｅｄ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｈｕｍａｎ　ｂｒｅａｓｔ　ｃａｎｃｅｒ　ｃｅｌｌｓ　ｗｉｔｈ　ａｎｔｉｅｓｔｒｏｇｅｎｓ　ａｎｄ　ｔｈｅ　ｖｉｔａｍｉｎ' Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓ　Ｔｒｅａｔ． ８５（１）, 200405, ５３-６３ *
JPN7012004507; Ｓａｕｎｄｅｒｓ　ＤＥ　ｅｔ　ａｌ．: 'Ｉｎｈｉｂｉｔｉｏｎ　ｏｆ　ｂｒｅａｓｔ　ａｎｄ　ｏｖａｒｉａｎ　ｃａｒｃｉｎｏｍａ　ｃｅｌｌ　ｇｒｏｗｔｈ　ｂｙ　１，２５-ｄｉｈｙｄｒｏｘｙｖｉｔａｍｉｎ　Ｄ３　ｃｏｍｂｉｎｅｄ　ｗｉｔｈ　ｒｅｔ' Ａｎｔｉｃａｎｃｅｒ　Ｄｒｕｇｓ． ６（４）, 199508, ５６２-９ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015227335A (ja) * 2009-01-27 2015-12-17 バーグ バイオシステムズ，エルエルシー 化学療法に付随する副作用を軽減するためのビタミンｄ３およびその類似体

Also Published As

Publication number Publication date
KR20090060306A (ko) 2009-06-11
NO20091191L (no) 2009-03-23
AU2007287099A1 (en) 2008-02-28
WO2008024485A3 (en) 2009-03-05
EP2425874A3 (en) 2013-05-15
EP2425874A2 (en) 2012-03-07
EP2063963A2 (en) 2009-06-03
IL197212A0 (en) 2009-12-24
WO2008024485A2 (en) 2008-02-28
CA2838089A1 (en) 2008-02-28
CA2661546A1 (en) 2008-02-28
CN101528309A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
JP2010501576A (ja) ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法
JP6740497B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US8501717B2 (en) Methods to treat and/or prevent mucositis
US20110021470A1 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
JP2008538580A (ja) 活性ビタミンｄ化合物またはその模倣体による、化学療法または放射線療法と関連する肺疾患の治療、予防、および改善
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130528